Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 900

1.

Therapeutic potential of RNA interference against cancer.

Takeshita F, Ochiya T.

Cancer Sci. 2006 Aug;97(8):689-96. Review.

2.

In vivo application of RNA interference: from functional genomics to therapeutics.

Lu PY, Xie F, Woodle MC.

Adv Genet. 2005;54:117-42. Review.

PMID:
16096010
3.

[In vivo siRNA delivery to tumor cells and its application to cancer gene therapy].

Takahashi Y, Nishikawa M, Takakura Y.

Yakugaku Zasshi. 2007 Oct;127(10):1525-31. Review. Japanese.

4.

siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.

Singh SK, Hajeri PB.

Drug Discov Today. 2009 Sep;14(17-18):859-65. doi: 10.1016/j.drudis.2009.06.002. Review.

PMID:
19540929
5.

Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.

Li SD, Huang L.

Curr Opin Investig Drugs. 2008 Dec;9(12):1317-23. Review.

PMID:
19037838
6.

Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.

Takahashi Y, Nishikawa M, Takakura Y.

Adv Drug Deliv Rev. 2009 Jul 25;61(9):760-6. doi: 10.1016/j.addr.2009.04.006. Review.

PMID:
19386274
7.
8.

Interfering with disease: opportunities and roadblocks to harnessing RNA interference.

Lieberman J, Song E, Lee SK, Shankar P.

Trends Mol Med. 2003 Sep;9(9):397-403. Review.

PMID:
13129706
9.
10.

The design and exogenous delivery of siRNA for post-transcriptional gene silencing.

Gilmore IR, Fox SP, Hollins AJ, Sohail M, Akhtar S.

J Drug Target. 2004 Jul;12(6):315-40. Review.

PMID:
15545082
11.

Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.

Chen Y, Huang L.

Expert Opin Drug Deliv. 2008 Dec;5(12):1301-11. doi: 10.1517/17425240802568505 . Review.

PMID:
19040393
12.

In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.

Golzio M, Mazzolini L, Ledoux A, Paganin A, Izard M, Hellaudais L, Bieth A, Pillaire MJ, Cazaux C, Hoffmann JS, Couderc B, TeissiƩ J.

Gene Ther. 2007 May;14(9):752-9.

PMID:
17344906
13.

Transkingdom RNA interference (tkRNAi) as a new delivery tool for therapeutic RNA.

Aigner A.

Expert Opin Biol Ther. 2009 Dec;9(12):1533-42. doi: 10.1517/14712590903307354. Review.

PMID:
19769540
14.

Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression.

He S, Zhang D, Cheng F, Gong F, Guo Y.

Mol Biol Rep. 2009 Nov;36(8):2153-63. doi: 10.1007/s11033-008-9429-7. Review.

PMID:
19117119
15.

RNAi-based drug discovery and its application to therapeutics.

Hokaiwado N, Takeshita F, Banas A, Ochiya T.

IDrugs. 2008 Apr;11(4):274-8.

PMID:
18379962
16.

Future prospect of RNA interference for cancer therapies.

Ashihara E, Kawata E, Maekawa T.

Curr Drug Targets. 2010 Mar;11(3):345-60. Review.

PMID:
20210759
17.

Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications.

Huang C, Li M, Chen C, Yao Q.

Expert Opin Ther Targets. 2008 May;12(5):637-45. doi: 10.1517/14728222.12.5.637 . Review.

PMID:
18410245
18.

Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.

DeVincenzo JP.

Early Hum Dev. 2009 Oct;85(10 Suppl):S31-5. doi: 10.1016/j.earlhumdev.2009.08.013.

PMID:
19833462
19.

Strategies for short hairpin RNA delivery in cancer gene therapy.

Wang SL, Yao HH, Qin ZH.

Expert Opin Biol Ther. 2009 Nov;9(11):1357-68. doi: 10.1517/14712590903236843. Review.

PMID:
19761417
20.

TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery.

Keates AC, Fruehauf J, Xiang S, Li CJ.

Biotechnol Genet Eng Rev. 2008;25:113-27. Review.

PMID:
21412352
Items per page

Supplemental Content

Support Center